Cryoport, Inc.
CYRX scores 42.0 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Moderate penalties (-7.8 points) reflect identified risk factors. The overall score balances these against the stock's fundamental strengths.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| CYRX | 42.0 | 6.3 | -1.7% | 35.5% | $423M |
| FER | 84.1 | 12.2 | 7.4% | 35.3% | $52.6B |
| NDSN | 77.2 | 35.1 | 3.8% | 17.4% | $16.2B |
| OMAB | 76.4 | 20.1 | 4.3% | 32.7% | $6.1B |
| ODFL | 76.3 | 39.8 | -0.9% | 20.4% | $40.8B |
| FAST | 73.1 | 42.6 | 8.7% | 15.3% | $51.7B |
| CSX | 71.5 | 26.5 | -3.1% | 20.5% | $78.9B |
| WWD | 71.3 | 47.8 | 7.3% | 12.4% | $23.0B |
| LECO | 71.3 | 31.5 | -4.4% | 11.6% | $15.6B |
| PCAR | 71.0 | 28.2 | -4.2% | 12.4% | $65.1B |
| CTAS | 70.8 | 41.9 | 7.7% | 17.5% | $80.3B |
| RYAAY | 69.9 | 13.0 | 3.8% | 11.6% | $36.1B |
| CPRT | 69.5 | 23.0 | 9.7% | 33.4% | $35.6B |
| FELE | 69.3 | 35.5 | -2.1% | 8.9% | $4.3B |
| NSSC | 68.9 | 34.5 | -3.8% | 24.7% | $1.7B |
| AEIS | 68.0 | 81.2 | 21.4% | 8.3% | $12.3B |
| Sector Average | 45.7 | 49.9 | 19.0% | -48.2% | โ |
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Stock is in a downtrend below the 200-day moving average. Price is below both the 50-day and 200-day SMAs, indicating sustained selling pressure.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $44M | $45M | $41M | $60M |
| Gross Profit | $21M | $21M | $19M | $27M |
| Operating Income | $-10M | $-10M | $-9M | $-14M |
| Net Income | $-7M | $105M | $-12M | $-19M |
| EPS (Diluted) | $-0.18 | $2.05 | $-0.28 | $-0.42 |
| Gross Margin | 48.2% | 47.0% | 45.4% | 45.8% |
| Operating Margin | -22.5% | -21.2% | -23.1% | -23.4% |
| Net Margin | -15.7% | 231.4% | -29.2% | -31.4% |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.